These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34143631)

  • 1. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
    Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
    J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
    Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
    Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
    Park A; Hwang J; Lee JY; Heo EJ; Na YJ; Kang S; Jeong KS; Kim KY; Shin SJ; Lee H
    Bioorg Med Chem Lett; 2021 Sep; 47():128226. PubMed ID: 34182093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
    ElHady AK; Abdel-Halim M; Abadi AH; Engel M
    J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
    Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
    Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
    Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
    J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
    Weber C; Sipos M; Paczal A; Balint B; Kun V; Foloppe N; Dokurno P; Massey AJ; Walmsley DL; Hubbard RE; Murray J; Benwell K; Edmonds T; Demarles D; Bruno A; Burbridge M; Cruzalegui F; Kotschy A
    J Med Chem; 2021 May; 64(10):6745-6764. PubMed ID: 33975430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
    Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
    PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer.
    Yang H; Wang X; Wang C; Yin F; Qu L; Shi C; Zhao J; Li S; Ji L; Peng W; Luo H; Cheng M; Kong L
    Eur J Med Chem; 2021 Jan; 210():113080. PubMed ID: 33310286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
    Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
    Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers.
    Irie T; Asami T; Sawa A; Uno Y; Taniyama C; Funakoshi Y; Masai H; Sawa M
    J Med Chem; 2021 Oct; 64(19):14153-14164. PubMed ID: 34607435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
    Henderson SH; Sorrell F; Bennett J; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Ashall-Kelly A; Hopkins Navratilova I; Walter DS; Elkins JM; Ward SE
    J Med Chem; 2021 Aug; 64(15):11709-11728. PubMed ID: 34342227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.
    Wilms G; Schofield K; Maddern S; Foley C; Shaw Y; Smith B; Basantes LE; Schwandt K; Babendreyer A; Chavez T; McKee N; Gokhale V; Kallabis S; Meissner F; Rokey SN; Dunckley T; Montfort WR; Becker W; Hulme C
    J Med Chem; 2024 Oct; 67(19):17259-17289. PubMed ID: 39344427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.